Delcath Systems Posts Mixed Q1 2026 Results Amid HEPZATO Growth
Event summary
- Delcath Systems reported Q1 2026 revenue of $25.0M, up 26% YoY, driven by HEPZATO KIT sales growth.
- HEPZATO KIT revenue rose 29% YoY to $23.3M, while CHEMOSAT revenue declined slightly to $1.7M.
- Net loss of $1.1M contrasted with $1.1M net income in Q1 2025, attributed to higher R&D and commercial expenses.
- Company repurchased 316,023 shares for $3.0M under its $25M share buyback program.
- Full CHOPIN trial results published in The Lancet Oncology showed improved progression-free survival for uveal melanoma.
The big picture
Delcath's Q1 2026 results highlight the growing clinical validation of HEPZATO KIT, particularly following the CHOPIN trial publication. However, the shift to net loss underscores the operational challenges of scaling commercial operations while maintaining profitability. The company's ability to leverage these clinical wins into sustained revenue growth will be critical as it competes in the interventional oncology space.
What we're watching
- Commercial Momentum
- Whether the 36% HEPZATO volume growth can be sustained amid increased competition in liver cancer treatments.
- Regulatory Validation
- How the inclusion of CHEMOSAT in ESMO–EURACAN guidelines will impact European market adoption.
- Operational Efficiency
- The pace at which Delcath can balance aggressive commercial expansion with rising R&D and SG&A costs.
Related topics